Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Tumor mutational burden and driver mutations: Characterizing the genomic landscape of pediatric brain tumors.

Pediatric blood & cancer - 1 Jul 2020

Patel Roshal R, Ramkissoon Shakti H, Ross Jeffrey, Weintraub Lauren

Abstract excerpt

BACKGROUND: Tumor mutational burden (TMB) and driver mutations are potential biomarkers to guide targeted therapy selection. Malignant gliomas with high TMB in children may preferentially benefit from treatment with immune checkpoint inhibitors (ICPIs). Higher TMB may relate to lower incidence of driver mutations, but this relationship has not been studied in pediatric brain tumors. PROCEDURE: Comprehensive...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers, Tumor
Share to Brain Neoplasms
Share to Cohort Studies

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Follow-Up Studies

Share to Genomics

Share to Glioma

Share to High-Throughput Nucleotide Sequencing

Share to Prognosis

Source

Identifiers

PMID: 32386112
DOI: 10.1002/pbc.28338

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Tumor mutational burden and driver mutations: Characterizing the genomic landscape of pediatric brain tumors.PMID 32386112Read ↗

Multi-institution analysis of tumor mutational burden and outcomes in pediatric CNS tumor patientsSemantic proximity Read ↗

Multi-institution analysis of tumor mutational burden and outcomes in pediatric central nervous system tumor patients.Semantic proximity Read ↗

Comprehensive Genomic Profiling of 282 Pediatric Low- and High-Grade Gliomas Reveals Genomic Drivers, Tumor Mutational Burden, and Hypermutation Signatures.Semantic proximity Read ↗

Pediatric brain tumors: the era of molecular diagnostics, targeted and immune-based therapeutics, and a focus on long term neurologic sequelae.Semantic proximity Read ↗

The impact of molecularly matched treatment and tumor mutational burden on pediatric brain tumor patient outcomesSemantic proximity Read ↗

Efficacy of Nivolumab in Pediatric Cancers with High Mutation Burden and Mismatch Repair Deficiency.Semantic proximity Read ↗

Immune checkpoint inhibitors in pediatric central nervous system tumors: biology, clinical experience, and translational pathways to precision immunotherapy.Semantic proximity Read ↗

Improving Diagnostic and Therapeutic Outcomes in Pediatric Brain Tumors.Semantic proximity Read ↗

Integrated Molecular and Clinical Analysis of 1,000 Pediatric Low-Grade Gliomas.Semantic proximity Read ↗

Review of the genomic landscape of common pediatric CNS tumors and how data sharing will continue to shape this landscape in the future.Semantic proximity Read ↗

New strategies in pediatric gliomas: molecular advances in pediatric low-grade gliomas as a model.Semantic proximity Read ↗

Genomic predictors of response to PD-1 inhibition in children with germline DNA replication repair deficiencySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.